|
注册号: Registration number: |
ChiCTR2400083708 |
|
最近更新日期: Date of Last Refreshed on: |
2024-04-30 15:00:31 |
|
注册时间: Date of Registration: |
2024-04-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于结肠镜检查的针刺对麻醉药物替代效应的循证评价研究 |
|
Public title: |
Evidence based evaluation of the substitution effect of acupuncture on anesthetic drugs based on colonoscopy examination |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于结肠镜检查的针刺对麻醉药物替代效应的循证评价研究 |
|
Scientific title: |
Evidence based evaluation of the substitution effect of acupuncture on anesthetic drugs based on colonoscopy examination |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
樊小农 |
研究负责人: |
樊小农 |
|
Applicant: |
Xiaonong Fan |
Study leader: |
Xiaonong Fan |
|
申请注册联系人电话: Applicant telephone: |
+86 139 0208 0823 |
研究负责人电话:
Study leader's |
+86 139 0208 0823 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fanxiaonong@163.com |
研究负责人电子邮件: Study leader's E-mail: |
fanxiaonong@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市西青区昌凌路88号 天津中医药大学第一附属医院 |
研究负责人通讯地址: |
天津市西青区昌凌路88号 天津中医药大学第一附属医院 |
|
Applicant address: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No.88 Changling Road. |
Study leader's address: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No.88 Changling Road. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津中医药大学第一附属医院 |
||
|
Applicant's institution: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
天津中医药大学第一附属医院 |
||
|
Affiliation of the Leader: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
TYLL2024[K]字 008 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津中医药大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
IRB of The First Teaching Hospital of Tianjin University of TCM |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-06 00:00:00 | ||
|
伦理委员会联系人: |
郑子琦 |
||
|
Contact Name of the ethic committee: |
Ziqi Zheng |
||
|
伦理委员会联系地址: |
天津市西青区昌凌路88号 天津中医药大学第一附属医院 |
||
|
Contact Address of the ethic committee: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No.88 Changling Road. |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27986258 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
天津中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市西青区昌凌路88号 天津中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No.88 Changling Road. |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家中医针灸临床医学研究中心开放课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
Open subject of National Clinical Research Center for Chinese medicine acupuncture and moxibustion |
||||||||||||||||||||||
|
研究疾病: |
无痛电子结肠镜 |
||||||||||||||||||||||
|
Target disease: |
painless electronic colonoscopy |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
验证针刺辅助麻醉应用于肠镜检查可替代传统麻醉药物芬太尼,从而起到减少不良事件发生率、提高麻醉安全性的作用。为针刺辅助解决麻醉安全问题提供高质量循证证据,推动针刺辅助麻醉在国内外医学界的广泛开展和应用,为麻醉高风险人群提供更加安全的麻醉方案。 |
||||||||||||||||||||||
|
Objectives of Study: |
To verify that acupuncture-assisted anesthesia can replace traditional anesthetic drugs like fentanyl in colonoscopy, thus reducing the incidence of adverse events and enhancing anesthesia safety. The aim is to provide high-quality evidence-based support for acupuncture-assisted solutions in anesthesia safety issues, promote the widespread adoption and application of acupuncture-assisted anesthesia in the medical community both domestically and internationally, and offer a safer anesthesia option for high-risk anesthesia populations. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
排除标准: 1. 拟行气管插管(包括喉罩)的患者; 2. 需要进行操作复杂的内镜诊疗技术; 3. 有肠道狭窄或粘连病史的患者; 4. 急性心力衰竭;不稳定型心绞痛;筛选前6个月内发生心肌梗死; 5. 患有严重呼吸道病变的患者; 6. 患有精神系统疾病及长期服用精神类药物史及认知功能障碍者; 7. 被判定为呼吸道管理困难(改良马氏评分为IV级)患者; 8. 肝肾等重要脏器功能严重受损的患者; 9. 筛选期开始前2年内有药物滥用史、吸毒史和酗酒史,酗酒即每日平均饮酒超过2单位酒精(1单位=360 mL啤酒或45 mL酒精量为40%的白酒或150 mL葡萄酒); 10. 未接受正规降压治疗或血压控制不佳的患者(筛选期坐位收缩压≥160 mmHg或≤90mmHg,和/或筛选期舒张压≥100mmHg); 11. 一个月内每天或近三个月内间断服用苯二氮卓类药物和/或阿片类药物; 12. 对阿片类药物、丙泊酚等药物及其药物组分过敏或有禁忌者; 13. 妊娠或哺乳期的女性; 14. 3个月内有生育计划的患者(包括男性); 15. 近3个月内作为受试者参加过任何临床试验; 16. 研究者认为不宜参加此试验患者。 退出标准:如果受试者满足下列一项或多项标准,则需终止试验: 1. 受试者任意时间主动撤回知情同意; 2. 在随机分组后发现受试者不合格; 3. 出现任何临床不良事件、实验室检查异常或其他医疗状况,导致继续用药受试者可能不再获益; 4. 肠镜检查总时长>30min; 5. 研究者认为无法继续试验治疗的其他原因 。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: Patients with any of the following conditions will not be included in this study: 1. Planned endotracheal intubation (including laryngeal mask) patients; 2. Patients requiring complex endoscopic diagnostic and treatment techniques; 3. History of intestinal stenosis or adhesion; 4. Acute heart failure; unstable angina; myocardial infarction within the past 6 months; 5. Patients with severe respiratory diseases; 6. Patients with psychiatric disorders, long-term use of psychiatric drugs, and cognitive impairment; 7. Patients judged to have difficult airway management (Mallampati score of IV); 8. Patients with severe impairment of major organ functions such as liver and kidney; 9. History of drug abuse, drug addiction, or alcohol abuse within 2 years before screening, where alcohol abuse is defined as daily average alcohol consumption exceeding 2 units (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine); 10. Patients not receiving regular antihypertensive treatment or with poor blood pressure control (sitting systolic blood pressure ≥160 mmHg or ≤90mmHg, and/or diastolic blood pressure ≥100mmHg during screening); 11. Use of benzodiazepines and/or opioids daily within the last month or intermittently in the last three months; 12. Allergy or contraindications to opioids, propofol, or their components; 13. Pregnant or breastfeeding women; 14. Patients with a plan to conceive within 3 months (including males); 15. Participation in any clinical trial within the last 3 months; 16. Patients deemed unsuitable for this trial by the researchers. Withdrawal Criteria: Trial participation will be terminated if a subject meets one or more of the following criteria: 1. Voluntary withdrawal of informed consent at any time by the participant; 2. Ineligibility discovered after randomization; 3. Any clinical adverse event, abnormal laboratory test, or other medical condition occurs that could result in no further benefit from the trial medication; 4. Total duration of colonoscopy >30 minutes; 5. Other reasons deemed by the researcher to discontinue trial treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-05-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用不等段长分段随机(Unequaled size block Randomization),在纳入第一例患者之前,由计算机程序生成随机数字序列(Random Number Sequence),以分中心作为分层因素,段长在4或6之间取值;通过中央随机系统(Central Randomization System)索取分组信息。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study use unequaled size block randomization. Before the inclusion of the first patient, a random number sequence was generated by a computer program, with sub centers as stratification factors, and segment lengths ranging from 4 to 6; Request grouping information through the central randomization system. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本试验采用受试者盲,由于本试验临床操作的特殊性,针灸医师无法致盲。研究者、结局评价者(兼数据收集者)、数据管理者、统计分析者对每个患者的治疗分配不知情。 |
|
Blinding: |
In this trial, the subjects were blinded. Due to the particularity of clinical operation in this trial, acupuncture physicians could not cause blindness. Researchers, outcome evaluators (also data collectors), data managers, and statistical analysts are unaware of the treatment allocation for each patient. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不适用 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表,电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF;Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |